TiGenix will present results from its Phase III trial of Crohn`s disease drug, named Cx601, at the upcoming 12th Annual Congress of the European Crohn`s and Colitis Organization (ECCO).
Dr. Julián Panés, Global Study Coordinator, will present new data from the Phase III ADMIRE-CD clinical trial conducted in Crohn`s disease patients with complex perianal fistulas who had an inadequate response to at least one conventional or biologic therapy.
“The efficacy of Cx601 in treatment-refractory complex perianal fistulas of CD patients was sustained for up to 1 year after a single administration,” said Dr. Marie Paule Richard, Chief Medical Officer at TiGenix. “The results also support the favorable tolerability of Cx601 over the long-term”.
TiGenix has an exclusive licensing and commercialization agreement for Cx601, ex-US, with Takeda and expects a decision from the EMA regarding its marketing authorization by year-end 2017. Takeda could launch Cx601 thereafter, said the company.